Wall Street analysts expect Castlight Health (NYSE:CSLT) to post ($0.08) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Castlight Health’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.22). Castlight Health posted earnings of ($0.05) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 60%. The firm is scheduled to issue its next earnings report after the market closes on Thursday, May 10th.

According to Zacks, analysts expect that Castlight Health will report full year earnings of ($0.12) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.11). For the next financial year, analysts expect that the firm will post earnings of $0.01 per share, with EPS estimates ranging from ($0.01) to $0.04. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Castlight Health.

How to Become a New Pot Stock Millionaire

Castlight Health (NYSE:CSLT) last issued its quarterly earnings results on Wednesday, February 21st. The software maker reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Castlight Health had a negative return on equity of 28.76% and a negative net margin of 42.28%. The firm had revenue of $37.00 million for the quarter, compared to analysts’ expectations of $36.36 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year.

A number of brokerages recently issued reports on CSLT. Zacks Investment Research cut Castlight Health from a “buy” rating to a “hold” rating in a report on Thursday, February 1st. ValuEngine raised Castlight Health from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 4th. Chardan Capital reissued a “buy” rating and set a $5.75 price objective (down previously from $6.30) on shares of Castlight Health in a report on Thursday, February 22nd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $5.00 price objective on shares of Castlight Health in a report on Wednesday, February 21st. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.04.

In other Castlight Health news, CFO Mangini Siobhan Nolan sold 18,201 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $3.63, for a total value of $66,069.63. Following the transaction, the chief financial officer now directly owns 120,788 shares in the company, valued at approximately $438,460.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John C. Doyle sold 10,644 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $3.63, for a total value of $38,637.72. Following the completion of the transaction, the chief executive officer now owns 157,422 shares in the company, valued at $571,441.86. The disclosure for this sale can be found here. Insiders sold a total of 33,184 shares of company stock worth $120,762 over the last 90 days. Corporate insiders own 24.38% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new position in Castlight Health during the 4th quarter worth approximately $126,000. First Quadrant L P CA bought a new position in Castlight Health during the 4th quarter worth approximately $167,000. Deutsche Bank AG grew its position in Castlight Health by 149.1% during the 4th quarter. Deutsche Bank AG now owns 142,486 shares of the software maker’s stock worth $533,000 after acquiring an additional 85,297 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Castlight Health by 5.1% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 262,059 shares of the software maker’s stock worth $1,127,000 after acquiring an additional 12,778 shares during the last quarter. Finally, Folger Hill Asset Management LP bought a new position in Castlight Health during the 4th quarter worth approximately $1,144,000. Hedge funds and other institutional investors own 43.30% of the company’s stock.

Shares of NYSE CSLT remained flat at $$3.40 during trading on Wednesday. The stock had a trading volume of 19,784 shares, compared to its average volume of 299,637. The stock has a market cap of $459.93, a PE ratio of -13.08 and a beta of 1.39. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.06 and a quick ratio of 2.06. Castlight Health has a 1 year low of $3.15 and a 1 year high of $4.75.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://theolympiareport.com/2018/04/16/zacks-brokerages-expect-castlight-health-cslt-will-post-earnings-of-0-08-per-share.html.

Castlight Health Company Profile

Castlight Health, Inc offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. Its technology offering aggregates data and applies analytics to make healthcare data transparent.

Get a free copy of the Zacks research report on Castlight Health (CSLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Castlight Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castlight Health and related companies with MarketBeat.com's FREE daily email newsletter.